Background and objectives: The purpose of this study is to determine the risk of constipation and to identify the signi cant risk factors for constipation in patients with gastrointestinal cancer using the Chinese version of the Constipation Risk Assessment Scale (CRAS-C), as well as to explore the complementary constipation risk factors in patients with gastrointestinal cancer, to improve the speci city of the CRAS-C in this population, and nally to provide a theoretical basis for constipation prevention.Research design and methods: A cross-sectional study involving multiple centers was conducted. A total of 190 patients with gastrointestinal cancer completed surveys that included demographic information, defecation habits, and the CRAS-C. The mean, SD, median, maximum, minimum, frequency, and percentage were used as indicators for the constipation risk and signi cant risk factors. The t-test and Chi-square tests were used to analyze constipation indicators in patients with gastrointestinal cancer.Results: 190 patients were 58.92±12.07 years of age.The total CRAS-C mean (SD) score was 13.22 (4.69).51 patients (26.8%) scored lower than 11, who were at the low risk level of constipation. 139 patients (73.2%) scored 11 or above, who were at the high risk level of constipation. The top 10 factors were insu cient liquid intake(81.1%), failure to consume bran products daily(78.9%), insu cient ber intake(77.9%), antiemetics (74.7%), cytotoxic chemotherapy (52.6%), colorectal/abdominal diseases (42.6%), opioid analgesics (35.3%), opioid analgesics(26.8%), calcium channel blockers (16.3%), endocrine disorders (14.2%). Chi square test showed that constipating for most of the past 3 months, ascites and ECOG score were complementary constipation risk factors in gastrointestinal cancer patients.
Conclusion:The ndings indicate that most gastrointestinal cancer patients were at a high risk of constipation. There are also several complementary constipation risk factors and CRAS-C can be further revised in future studies to make it more speci c in gastrointestinal cancer patients. Integrating CRAS into the pathway of constipation management, carrying out constipation risk screening for hospitalized cancer patients, building systematic constipation prevention plan based on risk assessment are important to reduce the incidence of constipation in patients with gastrointestinal cancer, and improve the quality of life.What Is Already Known About The Topic?The incidence of constipation in patients with gastrointestinal cancer is the highest and most serious among all cancer patients.The Chinese version Constipation Risk Assessment Scale (CRAS-C) demonstrated favourable content validity, predictive validity and interrater reliability in cancer patients in the previous study and could be used in the identi cation of cancer patients at risk of constipation. But it hasn't been used in gastrointestinal cancer patients.
What This Paper AddsThe risk of constipation in patients with gastrointestinal cancer is generally high, which needs to be...